Accepted for/Published in: JMIR Formative Research
Date Submitted: Dec 28, 2021
Open Peer Review Period: Dec 28, 2021 - Feb 22, 2022
Date Accepted: Dec 1, 2022
Date Submitted to PubMed: Dec 8, 2022
(closed for review but you can still tweet)
: Clinical Outcomes after Use of Inhaled Corticosteroids or Oral Steroids in a COVID-19 Telemedicine Clinic Cohort: A Retrospective Chart Review
ABSTRACT
Background:
Treatment in the outpatient population for illness due to COVID-19 focuses on symptoms but the effects on long term outcomes are unclear. COVID-19 cause significant inflammation in the body. Our goal was to evaluate outcomes in patients treated with inhaled corticosteroids (ICS) and/ or oral steroids in the acute/ sub-acute phase of COVID-19. In a retrospective chart review our team identified patients with COVID-19 that were followed by a telemedicine clinic and eventually referred to a post COVID clinic due to persistent symptoms of COVID-19. Of those patients requiring referral to the post COVID clinic, equal numbers of patients treated acutely/ sub-acutely with ICS and/ or oral steroids required referral to a pulmonary specialist. There was no clear benefit to one treatment regimen over the other. Consider side effects and cost when choosing a treatment option.
Objective:
To determine if there was a difference in long term outcomes when prescribed ICS versus oral steroids
Methods:
Chart review comparing new prescription ICS to new prescription oral steroid
Results:
No difference in long term outcome between the groups
Conclusions:
It is safe to prescribe ICS or oral steroids for symptom relief, but cost may be an issue
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.